+1-947-333-4405
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Short Communication
HIV and Pneumocystis Pneumonia (PCP): An Upto date
| Yanagisawa K* and Nojima Y | |
| Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan | |
| Corresponding Author : | Yanagisawa K Department of Medicine and Clinical Science Gunma University Graduate School of Medicine Maebashi, Gunma, Japan Tel: +81272208166 E-mail: kyanagi@gunma-u.ac.jp |
| Received: November 06, 2015; Accepted: December 28, 2015; Published: December 31, 2015 | |
| Citation: Yanagisawa K and Nojima Y (2015) HIV and Pneumocystis Pneumonia (PCP): An Upto date. J Infect Dis Ther 3:257. doi:10.4172/2332-0877.1000257 | |
| Copyright: © 2015 Yanagisawa, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
| Related article at Pubmed, Scholar Google | |
Abstract
Pneumocystis pneumonia (PCP) is one of an important opportunistic infections in patients with human immunodeficiency virus (HIV) infection or taking immunosuppressive agents. The diagnosis, therapy and prophylaxis have been well-established. The counts of CD4 positive T cells (CD4) is a risk factor of PCP in HIV-infected patients, and the prevalence of PCP in the patients having CD4<200/µl is almost a half of them in Japan. However, among HIV-infected patients, risk factor other than CD4 have not been established, although in patients with rheumatic diseases some factors have been reported. Recently, our team reported the association between the genotypes in gene coding mannose-binding lectin (MBL) and the prevalence of PCP in HIV-infected patients. It may confer the strategy of PCP prophylaxis in the immunocompromised patients.
